Figure 2.

Natural history of breast and prostate cancer: possible time points of clinical intervention and/or research for bone‐targeted agents. BC, breast cancer; BRCA1, breast cancer 1; BPs, bisphosphonates; CTIBL, cancer treatment‐induced bone loss; ER+, estrogen receptor‐positive; MAF, MAF BZIP transcription factor; PC, prostate cancer; ZA, zoledronic acid^a Investigational data only.^b Clinical evidence for bone mineral density (BMD) preservation and decreased incidence of fractures (denosumab).^c In postmenopausal women or associated with ovarian suppression. MAF‐negative may have a role in selection of BC patients to ZA.^d According to ABCSG‐18 study (only in postmenopausal women treated with aromatase inhibitors).^e In PC, ZA is the approved BP with strongest evidence and indication